Prognostic Evaluation Based on Dual-Time 18F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Radiation Therapy
Table 1
Clinical characteristics of the patients in the training cohort and the validation cohort. #Data are the number of patients and data in parentheses are the ratio.
Variable
Training cohort (n = 46)
Validation cohort (n = 24)
value
Age (years)
68 (26, 82)
67 (45, 84)
0.985
Sex#
0.156
Male
31 (67.4%)
12 (50.0%)
Female
15 (32.6%)
12 (50.0%)
T stage#
0.345
1
2 (4.3%)
1 (4.2%)
2
12 (26.1%)
5 (20.8%)
3
15 (32.6%)
13 (54.2%)
4
17 (32.7%)
5 (20.8%)
N stage#
0.102
0
30 (65.2%)
10 (41.7%)
1
16 (34.8%)
14 (58.3%)
ECOG#
0.458
0
8 (17.4%)
7 (29.2%)
1
23 (50.0%)
9 (37.5%)
2
15 (32.6%)
8 (33.3%)
CA19-9
365 (2, 2125)
132 (2, 1200)
0.504
Longest diameter (cm)
3.6 (1.5, 7.5)
3.9 (1.0, 6.3)
0.268
Location#
0.783
Head
34 (73.9%)
17 (70.8%)
Body/distal
12 (26.1%)
7 (29.2%)
Chemotherapy#
0.312
0
29 (63.0%)
18 (75.0%)
1
17 (37.0%)
16 (25.0%)
Dose
37.2 (30, 46.8)
36 (30, 46.8)
0.454
OS (month)
15.4 (7.5, 56.8)
14 (10.6, 43.9)
0.449
Data are the median and data in parentheses are the range. Chi-square test and Mann–Whiney U test are used to compare the difference between categorical and continuous variables in the training cohort and the validation cohort, respectively. ECOG, eastern cooperative oncology group; CA19-9, carbohydrate antigen 19–9; dose, radiotherapy dose (Gy).
